This lack of efficacy is generally associated with factors including off-target systemic toxicity, poor agonist bioavailability in tumor tissues, the fact that recombinant TRAIL has a short plasma half-life, and the fact that tumor cells often downregulate DR4/5 or upregulate anti-apoptotic proteins to survive [11]. Here, TNFRSF10A is linked to neoplasm.